Analysis

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Preclinical #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Multiplexing for biological relevance in high throughput screening

Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #RNA #Screening #Stem cells

1536 Plate Progress: Done deal but difficult transition?

By Dr John Comley After nearly 15 years of challenging maturity 1536 plate adoption (particularly in primary screening), finally appears to have taken hold. There is now available a broad range of 1536 plate types; an ever expanding variety of tools that make… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmokinetics #RNA #Screening #Target validation #Therapeutics #Toxicology

Harnessing fragment-based drug discovery at CRT

Himarnessing fragment-based drug discovery at CRT By Dr Andrew P Turnbull and Dr Martin E Swarbrick In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #PCR #Pharmacology #RNA #Screening #System biology #Systems biology #Therapeutics

Structure-Based Drug Design – Will crystallisation ‘chaperones’ make all proteins crystallisable?

Structure-Based Drug Design – Will crystallisation ‘chaperones’ make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Imaging #Immunology #Molecular medicine #Oncology #Pharmacology #Pharmokinetics #Preclinical #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Molecular Imaging Approaches – How can they help drug development?

By Dr Susanta K. Sarkar The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genomics #Immunology #Lead discovery #Microbiology #Molecular medicine #Oncology #Organic chemistry #Preclinical #Regulatory #RNA #Therapeutics

A perspective on scientific innovation in the pharmaceutical industry

Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Gene therapy #High Content Screening #Imaging #Immunology #Lead discovery #Regulatory #RNA #Stem cells

Stem Cell Therapies: Assessing the commercial opportunity

Share Share Tweet Email Stem Cell Therapies: Assessing the commercial opportunity Stem Cell Therapies: Assessing the commercial opportunity By Su Webber, Andrew Millest and Mark Williams Restructuring and reorganisation is routine and relentless in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Enabling technologies #Genetics / genomics #Genomics #Organic chemistry #PCR #Pharmokinetics #RNA #Sequencing

Bringing Cost and Process Efficiency to Next Generation Sequencing

Bringing Cost and Process Efficiency to Next Generation Sequencing By Dr Fred P. Ernani, and Dr Emily M. LeProust While next-generation sequencing has revolutionised the way genomes are sequenced, this technology possesses a fundamental weakness – the inability to easily target specific regions of a genome. To… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Organic chemistry #Patent Law #RNA #Screening #Target validation #Toxicology

Overcoming the Limitations of Chemical Structure

Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #High throughput screening #Lead discovery #Lead optimisation #RNA #Screening

Modular Automation for Screening: A cost/benefit analysis

Modular Automation for Screening: A cost/benefit analysis By Dr Jonathan Wingfield Cost is now a key driver for pharmaceutical companies and in many respects shapes the capital, revenue and resource decisions that have to be made during the drug discovery process. Where companies are resource rich, the need… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Business #Cell / tissue culture #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Lead discovery #Pharmacology #Pharmokinetics #Preclinical #QA/QC #System biology #Systems biology

LIMS vs ELNs – Arch enemies or best of friends?

LIMS vs ELNs – Arch enemies or best of friends? By David Morris Since the first appearance of laboratory information management systems (LIMS) in the late 1960s, this technology has become commonplace in many, if not most, research and commercial laboratories. This considerable development… Read More

#Archive

#ADME / Tox #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Pathology #PCR #RNA #Screening #Sequencing #Stem cells #Target validation #Toxicology

Recent Technology Advances Transforming Pharmaceutical Drug Discovery and Development

Recent Technology Advances Transforming Pharmaceutical Drug Discovery and Development By Dr Coiln Brenan, and Dr Bill LaMarr The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more… Read More

#Archive

#Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Lead discovery #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Early Validation: The difference between success and failure?

Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Target validation #Therapeutics #Toxicology

Restructuring Proteomics to Enable Personalised Cancer Care

Restructuring Proteomics to Enable Personalised Cancer Care By Dr Henry Rodriguez The genomics community has made great strides in our understanding of the molecular basis of cancer and these advances are slowly beginning to change the way we diagnose and treat patients. But genomic studies alone cannot… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Microbiology #Molecular medicine #Oncology #PCR #Pharmacogenomics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Generation II DNA Sequencing Technologies

Generation II DNA Sequencing Technologies By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #PCR #Pharmacology #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Target validation #Therapeutics

Stem Cell Applications and Opportunities in Drug Discovery

Stem Cell Applications and Opportunities in Drug Discovery By Dr Mark A. Thiede The high attrition rate of late stage drug candidates has led the pharmaceutical and biotech industries to a reassess the in vitro models used to select and validate drug targets and subsequent lead molecules. Read More

#Archive